Evaluation of a Potential Tigecycline‐Warfarin Drug Interaction

  title={Evaluation of a Potential Tigecycline‐Warfarin Drug Interaction},
  author={James J. Zimmerman and Donald G. Raible and Dawn Harper and Kyle T. Matschke and John L. Speth},
  journal={Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy},
Study Objective. To evaluate the potential for a clinically significant drug interaction between tigecycline and warfarin by using pharmacokinetic and anticoagulant assessments. 

Phase 1 Study of the Effect of Icosapent Ethyl on Warfarin Pharmacokinetic and Anticoagulation Parameters

Co-administration of these drugs was safe and well tolerated in this study of healthy adult subjects and IPE 4 g/day did not significantly change the single-dose AUC0–∞ or Cmax of R- and S-warfarin or the anticoagulation pharmacodynamics of warfarin when co-administered as racemic Warfarin at 25 mg.

Review of Tigecycline: Focus on Clinical Utilization

The antimicrobial profile and available clinical data for the first member of the glycylcycline class, tigecycline, may provide a therapeutic option in select patients, given its broad spectrum of activity, including multi-drug resistant (MDR) strains.

Tigecycline: a critical safety review

The safety profile of tigecycline, a broad spectrum antibiotic covering against many MDR organisms, is reviewed, including its side effects and drug interactions.

Beware of drug interaction between tigecycline and tacrolimus

A case of marked elevation in tacrolimus concentration after use of tigecycline in a renal transplant recipient in a patient with a background of diabetic kidney disease is reported, and similar observation has been reported in another renal transplants recipient, accompanied by resolution of hyperkalaemia.

A review of tigecycline--the first glycylcycline.

  • L. Peterson
  • Medicine, Biology
    International journal of antimicrobial agents
  • 2008

Influence of ORM1 polymorphisms on the maintenance stable warfarin dosage

ORM1 is identified as another polymorphic gene affecting warfarin dose requirements, and ORM1 *S carriers require lower maintenance doses to achieve and maintain an optimal level of anticoagulation.

Tigecycline antibacterial activity, clinical effectiveness, and mechanisms and epidemiology of resistance: narrative review

  • S. YaghoubiA. Zekiy Farajolah Maleki
  • Medicine, Biology
    European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology
  • 2021
Tigecycline showed in vitro susceptibility to Coxiella spp, Rickettsia spp.

The Development of Third-Generation Tetracycline Antibiotics and New Perspectives

The tetracycline antibiotic class has acquired new valuable members due to the optimisation of the chemical structure, and new derivatives are developed and studied primarily for the antibiotic effect and other biological effects.



Clinical Pharmacokinetics of Doxycycline and Minocycline

The influence of age, renal disease, malnutrition and hyperlipidaemia is reviewed, together with the main pharmacokinetic interactions of doxycycline and minocycline.

Human P450 metabolism of warfarin.

Systematic overview of warfarin and its drug and food interactions.

The consistency of reports of interactions with azole antibiotics, macrolides, quinolones, nonsteroidal anti-inflammatory drugs, including selective cyclooxygenase-2 inhibitors, selective serotonin reuptake inhibitors, omeprazole, lipid-lowering agents, amiodarone, and fluorouracil suggests that coadministration with warfarin should be avoided or closely monitored.

Antibiotics acting on the translational machinery

To aid design of new antibiotics, a detailed understanding of the mechanisms of vancomycin must be developed to help design of these agents.

The stereoselective interaction of warfarin and metronidazole in man.

  • R. O'Reilly
  • Medicine
    The New England journal of medicine
  • 1976
The interaction of racemic warfarin and metronidazole is stereoselective and can be lessened or even avoided by use of R (+)-warfarin alone for long-term therapy.

Effect of St John's wort and ginseng on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects.

St John's wort significantly induced the apparent clearance of both S-warfarin and R-warFarin, which in turn resulted in a significant reduction in the pharmacological effect of rac-war Farin, and Coadministration of warfarin with ginseng did not affect the pharmacokinetics or pharmacodynamics of either S- Warfarin or R-Warfarin.

Activity of Tigecycline (GAR-936), a Novel Glycylcycline, against Enterococci in the Mouse Peritonitis Model

Tigecycline displayed a protective effect against all strains tested, including two with Tn925 (from the Tn916 family), which contains the Tet(M) tetracycline resistance determinant, as well as VanA and VanB strains.

Warfarin. Stereochemical aspects of its metabolism and the interaction with phenylbutazone.

It is concluded that inhibition of the metabolism of S warfarin provides one mechanism for the augmented anticoagulation which follows phenylbutazone.

Efficacy and safety of tigecycline monotherapy compared with vancomycin plus aztreonam in patients with complicated skin and skin structure infections: Results from a phase 3, randomized, double-blind trial.

  • S. SacchidanandR. Penn G. Rose
  • Medicine
    International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases
  • 2005

Safety and Efficacy of Tigecycline in Treatment of Skin and Skin Structure Infections: Results of a Double-Blind Phase 3 Comparison Study with Vancomycin-Aztreonam

Tigecycline was shown to be safe and effective for the treatment of complicated skin and skin structure infections and the numbers of patients reporting adverse events were similar in the two groups, with increased nausea and vomiting rates in the tigecYcline group and an increased incidence of rash and increases in alanine aminotransferase and aspartate aminotsferase levels in the combination vancomycin and aztreonam group.